Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | INPPL1 | O15357 | 2/20 | 0.38 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2469681 | 0.89 | IRAK4 (0.37) | INPPL1INPP5AALDH1A1POLBIRAK4 | |
| SCHEMBL12313590 | 0.80 | INPPL1 (0.55) | INPPL1INPP5AALDH1A1PTPN5 | |
| SCHEMBL25241450 | 0.74 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL25284111 | 0.74 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL12337537 | 0.74 | INPPL1 (0.51) | INPPL1INPP5AALDH1A1MAPTMAPK1 | |
| SCHEMBL12337535 | 0.72 | CYP3A4 (0.40) | — | |
| SCHEMBL2363073 | 0.71 | MAOB (0.40) | ALDH1A1IRAK4KMT2AMCL1 | |
| SCHEMBL12313586 | 0.69 | INPPL1 (0.49) | INPPL1ALDH1A1 | |
| SCHEMBL2354041 | 0.69 | INPPL1 (0.49) | INPPL1INPP5AALDH1A1IRAK4 | |
| SCHEMBL7325861 | 0.68 | IRAK4 (0.43) | ALDH1A1POLBIRAK4ELANEMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-8354454-B2 | Prodrugs of oxazolidinone CETP inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-01-15 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2011-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110218177-A1 | PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS | CETP, SLCO2B1, OXA1L | INPPL1 1753/4885INPP5A 1715/4885ALDH1A1 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.